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Abstract.  An inhibitor of neovascularization from the 
conditioned media of scapular chondrocytes estab- 
lished and maintained  in serum-free culture has been 
isolated and characterized.  To determine whether this 
chondrocyte-derived inhibitor  (ChDI) was capable of 
inhibiting  neovascularization in vivo, this protein was 
assayed in the chick chorioallantoic membrane assay. 
ChDI was a potent inhibitor of angiogenesis in vivo 
(4/xg  =  87 % avascular zones).  This inhibitor  is also 
an inhibitor of fibroblast growth factor-stimulated cap- 
illary endothelial cell (EC) proliferation and migra- 
tion,  as well as being an inhibitor of mammalian  col- 
lagenase.  ChDI significantly suppressed capillary EC 
proliferation in a dose-dependent, reversible manner 
with an IC5o (the inhibitory concentration at which 
50%  inhibition is achieved) of 2.025/~g/ml.  Inhibition 
by ChDI of growth factor-stimulated capillary EC 
migration  was also observed using a modified Boyden 
chamber assay (IC50 =  255 ng/ml).  SDS-PAGE analy- 
sis followed by silver staining  of ChDI purified to ap- 
parent homogeneity revealed a single band having an 
Mr of 35,550.  Gel elution experiments demonstrated 
that only protein eluting at this molecular weight was 
anti-angiogenic.  These studies are the first demonstra- 
tion that chondrocytes in culture can produce a highly 
enriched, potent inhibitor of neovascularization which 
also inhibits collagenase. 
C 
ARTILAGE is  a highly  specialized  connective tissue 
whose characteristic  cell type is the chondrocyte. 
One major function of these cells is the synthesis of 
the cartilage extracellular  matrix which enables the tissue to 
withstand compressive stresses (2).  An equally important 
but less understood function of individual  chondrocytes is 
the synthesis of cartilage-specific  macromolecules, the phys- 
iological  significance of many of which still remains poorly 
understood (2). 
Cartilage  is an interesting  and unique tissue in that  it is 
avascular  and relatively  tumor-resistant.  Early work from 
several laboratories, including  our own, had demonstrated 
that cartilage contains an inhibitor of neovascularization  (4, 
9, 21, 26-28), but no single  cartilage-derived  macromole- 
cule was purified or identified. Despite early suggestions that 
protease inhibitory  activity derived  from  cartilage  might 
play a role in such processes as the prevention of connective 
tissue breakdown, inhibition of tumor cell invasion, and inhi- 
bition of angiogenesis  (21, 22, 25, 27, 37, 39, 41-43, 46, 47, 
51), the physiological significance of a cartilage-derived anti- 
protease activity remained to be elucidated (33).  Recently, 
a  cartilage-derived  collagenase  inhibitor  (CDI)  has  been 
identified,  purified, and shown to be antiangiogenic  in vivo 
and in vitro (34, 36). 
A number of groups have recently become interested in the 
role of the chondrocyte relative to the process of neovascu- 
larization.  Takigawa et al.  (49) have reported that articular 
chondrocyte conditioned media (CM) ~  contains an inhibitor 
of angiogenesis,  yet this  inhibitor has never been purified 
or identified.  Pepper and co-workers have recently demon- 
strated that chondrocytes,  when cocultured with endothelial 
cell (EC) aggregates in a collagen gel matrix, inhibit capil- 
lary EC sprout formation.  Addition of anti-TGF-B antibodies 
to the coculture system only reduced by 50% the inhibitory 
effect of the chondrocytes on sprout formation.  Pepper et al. 
(40) concluded that these results indicated the presence of an 
additional  antiangiogenic  factor. 
To identify the antiangiogenic  factor produced by cultured 
chondrocytes,  we have established and maintained  scapular 
chondrocytes in serum-free culture and have demonstrated 
that these cells produce a potent inhibitor  of angiogenesis. 
This chondrocyte-derived angiogenesis  inhibitor (ChDI)  is 
also an inhibitor  of mammalian  collagenase. 
1.  Abbreviations  used  in  this  paper:  CAM,  chorioallamoic membrane; 
ChDI, chondrocyte-derived inhibitor; CM, conditioned media; EC, endo- 
thelial cell; aFGE acidic FGF; bFGF, basic FGF; IC50, the inhibitory con- 
centration at which 50% inhibition is obtained. 
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Ceil Culture 
Chondroe~.es.  Bovine scapular chondrocytes were isolated from the scapu- 
lar cartilage of newborn calves (I-14 d old) according to the method of 
Klagsbrun (20) and primary cultures were established and maintained in 
serum-free culture (see Fig.  1). Veal scapulae  were obtained from Arena 
Co. (Hopkinton, MA) within 24 h of slaughter. Briefly, under sterile condi- 
tions the scapular cartilage was excised from the scapular bone and scraped 
clean of muscle and connective tissue using first a  periosteat elevator 
(Arista, New York, NY) and then a  scalpel  blade (no,  t0; Bard-Parker, 
Rutherford, NJ). The cleaned cartilage was cut into pieces (0.5  x  0.5 era) 
and incubated with Clostridial collngenase (CLS 2; Worthington,  Freehold, 
NJ)  (2.0  mg/ml  PBS  containing Ca  +2  and  Mg  +2  [Gibco Laboratories, 
Grand Island, NY]) for 12-24 h. The cell suspension was filtered to remove 
undigested cartilage and was  washed twice with PETS. Cells were then 
counted using a hemocytometer (Scientific Products,  McCraw Park, IL) and 
1 ￿  107 viable cells (as determined by the exclusion of trypan blue) were 
plated into 75-cm tissue culture flasks (Falcon Labware, Lincoln Park, N  J) 
containing HAM F-12 (Flow Laboratories, Inc.,  McLean,  VA) supple- 
merited with 50 #g/mi ascorbic acid (Eastman Kodak Co., Rochester, NY). 
Chondrocyte CM was harvested twice a week and the primary chondrocyte 
cultures were refed with above media. Upon collection, the media was dia- 
lyzed exhaustively against distilled water (tool wt cut off 3,500) (Spectra/ 
Pot; Fisher Scientific Co., Pittsburgh, PA) and lyophilized.  CM was har- 
vested from several different tissue culture flasks. Scapular cartilage was ob- 
tained from at least three calf shoulders per preparation. 
Endothelial Cells.  Capillary ECs, isolated from bovine adrenal cortex 
(13) were the generous gift of Katherine ButterfieM and Dr.  J.  Folkman 
(Children's Hospital, Boston, MA). These ceils were maintained in culture 
in DME (Gibco Laboratories) with 10%  calf serum (Hyclone,  Logan, 
Utah) (DME/IO),  supplemented with retina-derived  growth factor (5 ~d/ml) 
(16) in preparation for the assays. These cells were demonstrated to be en- 
dothelial by staining with antisera to yon Willebrand factor (18) and by their 
uptake of fluoresceinated,  acetylated low density lipoprotein (53). 
Cell Proh'feration  Assays 
Capillary ECs were plated in DME/5 onto gelatin-coated 0.5% gelatin, 
wt/vol [Difco, Detroit, MI]) 24-well tissue culture dishes (Nunc, Roskilde, 
Denmark). At the indicated times, inhibitor samples and acidic FGF (aFGF) 
(F.G,F. Co., La Jolla, CA) were added to some of the wells.  Wells con- 
taining PBS alone and PBS and aFGF were inetuded as controls. These sub- 
stances were added simultaneously in volumes that did not exceed  10% of 
the final volume,  After incubation with the test substances for the desig- 
nated times, medium was aspirated, ceils were washed with 0.5 ml of PBS, 
removed by trypsinization (0.5  ml 0.05%  trypsin-O.02%  EDTA;  Giheo 
Laboratories), and counted electronically with a celt counter (Coulter Elec- 
tronics, Hialea_h, FL). 
This cell counting assay was supported by an additional proliferation as- 
say which measures the number of endothelial ceils in culture on the basis 
of the colorimetric measurement of cellular acid phosphatase (7). 
Reversibility of  ChDI Inhibition of  Capillary 
EC Growth 
To determine whether the inhibition of capillary EC proliferation was due 
in part to cytotoxicity, reversibility studies were conducted as described pre- 
viously for capillary EC (3, 8, 36). The proliferation assay described above 
and in Fig.  5 was repeated with ChDI (ICs0 concentration), with the fol- 
lowing modification: on day 5,  cells from representative wells  of three 
conditions-cells unexposed to either growth factor or ChDI, cells exposed 
to growth factor alone, and cells exposed to both growth factor and ChDI- 
v,~re counted as usual. Duplicate wells of each condition were also washed 
twice with 0.5 mi PBS and either re,  fed with DME/5 alone (controls) or with 
DMEf5 and growth factor. These wells were then counted 3 d later. Cells 
were examined morphologically under light microscopy. 
Migration Assays 
Capillary EC migration was measured using a modification of the Boyden 
chamber assay (10). Blind well chambers (no. O25-187; Nettroprobe,  Pleas- 
anton,  CA)  were  utilized.  Polyearbonate membranes with 8-/~m pores 
(Nucleopore, Pleasanton, CA) were precoated with human fibronectin (6.67 
~g/ml in PBS; Cooper, Freehold, NJ). Basic FGF (bFGF) (Takeda Chemi- 
cal Co., Osaka, JP) was added to the lower wells. The upper wells received 
capillary EC and increasing concentrations  of ChDI. Control wells received 
DME/1, either with or without FGE After incubation, the cells on the upper 
surface of the membrane were wiped off by drawing the membrane over a 
wiper blade (Neuroprobe, Freehold, NJ) as described previously (36). The 
cells which had migrated through the membrane onto the lower surface 
were fixed in 2 % glutaraldehyde  (Sigma Chemical Co., St. Louis, MO) fol- 
lowed  by  MeOH  (4~  and  stained  with  hematoxylin.  Migration was 
quantified by counting the number of cells on the lower surface  in 16 oil 
immersion fields per well. 
Angiogenesis Assays 
To determine whether or not ChDI could inhibit angingenesis  in vivo, the 
chorioallantoic membrane (CAM) assay was utilized.  Briefly, on day 3 of 
development, fertilized chick embryos were removed from their shells and 
placed in plastic petri dishes (1005;  Falcon Labware).  They were main- 
tained in humidified 5% CO2 at 37~  On day 6 of development, san~les 
of ChDI were mixed in methylcellulose disks and applied to the surfaces 
of the growing CAMs above the dense subectodermaI plexus.  After 48 h 
exposure of the CAMs to ChDI, CAMs were observed using a binocular 
dissecting microscope at ￿  7-10 magnification.  The CAMs were injected 
intravascularly with India-intdLiposyn as described previously  (50). Other 
CAMs were prepared for histological analysis by first being fixed in forma- 
lin (Fisher Scientific Co., Fairlawn,  NJ) at room temperature and rinsed in 
0.t M cacodylate buffer, pH 7.4. The specimens were embedded in JB-4 
plastic (Polyseiences,  Warrington, PA) at 4~  and 3-/~m sections were cut 
using a Reichert 2050 microtome. Sections were stained with toluldine blue 
and micrographs were taken on a Zeiss photomicroscope using Kodak TM 
x  100 and a green filter. 
Protein Assays 
Protein concentration of chondrocyte CM and ChDI was determined by the 
Lowry method (29) using BSA as the standard. 
Polyacrylamide Gel Electrophoresis 
SDS-PAGE was performed according to the method of Laemmli (24); 0.75- 
mm  t5%  gels were used.  Samples were reduced with mercaptoethanol 
(Sigma Chemical Co.) before application. Silver staining was carried out 
according to a modification of the method of Wray et al. (54). The gel was 
fixed for 30 rain in 50% methanol (Pierce Chemical Co., Rockford,  ILL 
10% acetic acid followed by an overnight incubation in 5% methanol, 7% 
acetic acid.  The next morning, gels  were placed in 10% glutaraldehyde 
(Sigma Chemical Co.) for 30 rain and then washed  with four changes of 
water over a period of 2 h. Gels were then silver stained for 15 min and 
developed as described by Wray et aL (54). Unless otherwise indicated, re- 
agents were obtained from Fisher Scientific  Co.  (Fairlawn, NJ). 
Chromatography 
To isolate ChDI from the chondrocyte CM, media were exhaustively  dia- 
lyzed against distilled water before chromatography.  The dialyzed  samples 
were lyophitized  and diluted in 0.1 M Tris-HCl (Schwarz Mann, Biotec, 
Cleveland, OH) pH 7.6, containing 4 M guanidine-HC1 (ICN Biomedicals, 
Cleveland, OH), 0.00t  M CaCl2 and 0.02 % sodium azide.  Alternatively, 
samples were diluted and chromatograpbed in buffer containing 0.05 M 
Tris-HCl, pH 7.6 containing 0.2 M NaCl and 0.001 M CaCl2 (coUngenase 
assay buffer [CAB]).  Samples of chondrocyte CM (2-4 mg protein) were 
then applied to a Scphadex G-75 (Superfine) (Pharmacia, Uppsala, Sweden) 
column (1.6 ￿  50 cm) equilibrated with either of the appropriate buffers 
at a flow rate of t0 rnl/h. 1-ml fractions were collected. Molecatlar weight 
markers used were blue dextran (Mr 2  X 20% ovalbumin (Mr 43,000), 
chymotrypsinogen (Mr 26,000),  and ribonuclease A (Mr 13,000).  Unless 
otherwise indicated, all reagents were obtained from Sigma Chemical Co. 
Fractions enriched in collagenase inhibitory  activity (1 inhibitory  unit, i.e., 
ICs0 or greater) were pooled for further study. 
CoUagenase  Inhibitor Assays 
Colfagenase  inhibitory activity was determined using a modification (38) 
of a radiometric collagen film assay (19) as described by us previously. 
The lournal of Cell Biology, Volume 119, 1992  476 Figure I. Phase-contrast micrograph depicting confluent monolayer of scapular chondrocytes. The ceils are refed twice a week with HAM 
F-12 supplemented with 50 #g/ml ascorbic acid. The chondrocytes are polyhedral and demonstrate their characteristic cobblestone mor- 
phology. 
Elution of  Anffangiogenic Activity  from 
SDS-Polyacrylamide Gels 
After chromatography on Sephadex G-75,  ChDI  was subjected to  dec- 
trophoresis on SDS-PAGE slab gels as described above with the following 
exceptions. Samples were dissolved in buffer that did not contain mercap- 
toethanol. Samples were incubated at 37"C for 1 h before application to gels 
rather than being boiled. Electrophoresis was carried out at 250 V for 1 h 
as above. After electrophoresis, lanes containing protein markers together 
with a lane containing ChDI were cut out of the slab and silver stained ac- 
cording to a shortened protocol (38). Gels were fixed for 30 rain in 50% 
methanol, 10 % acetic acid. The water washes after glutaraldehyde fixation 
were shortened to 20 min each. While gels were being fixed and stained, 
the unstained portion was stored at 4~  in the refrigerator. The stained gels 
were placed in 50% methanol until they were the same size as the unstained 
gels. Gels were then lined up and regions corresponding to these approxi- 
mate Mr were excised: 65-67, 31-40, 21.5-31,  15-21.5, and 13-15  kD. Al- 
though no other protein bands were observed after electrophoresis on the 
silver-stained SDS-PAGE gel (see Fig. 3), we chose to include these other 
regions of the gel as controls in our elution studies because cartilage has 
been shown to contain other eoUagenase inhibitors (15, 36, 38). Some areas 
from lanes in which only sample buffer had been electrophoresed were ex- 
cised to serve as controls. Gel slices were minced finely and incubated for 
24 h in 1-2 ml of CAB containing 0.5% Brij 35 (38). The eluate was dia- 
lyzed overnight at 4"C against 1,000 vol of CAB containing 0.05%  Brij 35. 
Protein concentrations of ChDI were estimated by comparing the intensities 
of  silver-stained  ChDI bands on SDS-PAGE gels to those of  the protein stan- 
dards as previously described (45).  Samples were assayed both for their 
ability to inhibit capillary EC proliferation and collagenase as described 
above. To test these eluted samples for their ability to inhibit capillary EC 
proliferation, Brij  35  was removed from each eluted sample using pre- 
packed columns of Extracti-Gel D  (Pierce Chemical Co.) according to 
manufacturer's specifications. 
Results 
Primary cultures of chondrocytes isolated from the scapular 
cartilage of  newborn calves were established and maintained 
in HAM F-12 supplemented with ascorbic acid (Fig. 1). The 
serum-free nature of these primary  chondrocyte cultures 
eliminated the need to remove any contaminating serum- 
derived proteins. To further purify and characterize the ChDI 
from the serum-free chondrocyte CM, the media was chro- 
matographed on a Sephadex G-75 (superfine) column eluted 
in buffer containing 0.01 M  Tris-HC1,  pH 7.6, containing 
4  M guanidine-HC1 and 0.001 M CaCI~. Fractions were then 
screened for collagenase inhibitory activity as described pre- 
viously (36, 38); inhibitory activity was recovered in a mo- 
lecular weight region centered at ~32,000  (Fig. 2).  Frac- 
tions enriched in collagenase inhibitory activity from this 
step were pooled and protein  concentrations determined. 
SDS-PAGE  analysis of ,~5  gg of ChDI followed by silver 
staining revealed a band at an Mr of 35,550  (Fig. 3).  This 
same result was observed even when 10 and 15/~g of ChDI 
were electrophoresed. 
To determine whether ChDI was capable of inhibiting an- 
giogenesis in vivo, the chick CAM assay (50) was used. Fig. 
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Figure 2.  Sephadex G-75 chromatography. Chondrocyte CM was 
exhaustively dialyzed against distilled water and concentrated by 
lyophilization. CM samples (2--4 nag) were diluted in 0.1 M Tris- 
HCI, pH 7.6, containing 4 M guanidine-HCl, and 0.001 M CaC12 
and applied to a Sephadex G-75 (superfine) column (1.6 x  50 cm) 
equilibrated with the buffer described above at a flow rate of 10 
ml/h; 0.8-ml fractions were collected and 75-ul aliquots were as- 
sayed for collagenase inhibitory activity. ---, A280; e, percentage 
of inhibition. 
Figure  3.  Silver-stained  SDS- 
PAGE of ChDI.  SDS-PAGE was 
performed on ChDI (5 ug) accord- 
ing to the method of  Laemmli (24); 
samples were reduced  with  mer- 
captoethanol  before  application. 
Silver staining was carried out by a 
modification  of  the method of  Wray 
et al. (54). To determine molecular 
weight, the following  reduced stan- 
dard  proteins  were  used:  phos- 
phorylase b, BSA, ovalbumin, car- 
bonic anhydrase, soybean trypsin 
inhibitor, and lysozyme (Bio-Rad 
Laboratories, Richmond, CA). 
4 a  shows the significant inhibition of embryonic neovascu- 
larization as evidenced by the large avascular zone, caused 
by 4-/~g samples of ChDI placed in methylcellulose discs, af- 
ter 48 h of exposure to ChDI.  This effect was observed in 
87 % of the eggs tested. This observation was reproduced in 
four separate sets of  CAM assays using different ChDI prepa- 
rations. Inhibitor eluted from G-75 columns in the absence 
of 4 M guanidine-HC1 also demonstrated the same amount 
of inhibition.  In  contrast,  control  CAMs  implanted  with 
empty methylcellulose discs did not develop avascular zones 
(Fig. 4 b). Histological studies of  ChDI-treated CAMs reveal 
an absence of normal capillaries (Fig. 4 c) relative to con- 
trois which show normal vascular development (Fig. 4 d). 
To understand the mechanism(s) by which ChDI inhibits 
angiogenesis we studied the effect of  this inhibitor on two key 
components of  the angiogenic process, capillary EC prolifer- 
ation and migration (1). By utilizing the specific cells in- 
volved in angiogenesis and by stimulating them with known 
angiogenesis factors, we could mimic the angiogenic pro- 
cess in vitro. Unfractionated serum-free media conditioned 
by these primary chondrocyte cultures inhibited aFGF-stimu- 
lated capillary EC proliferation in a dose-dependent manner, 
with an IC50 of 200/~g/ml  (Fig.  5 a).  The ChDI obtained 
from the G-75 chromatography step inhibited capillary EC 
proliferation in  a  dose-dependent manner with an IC5o of 
2.025/~g/ml (Fig. 5 b). An additional bioassay which deter- 
mines the number of endothelial cells in culture on the basis 
of  colorimetric measurement of  cellular acid phosphatase (7) 
was also utilized to determine the effect of ChDI on capillary 
EC proliferation. Results from this assay verified the cell 
counting assay results (data not shown). 
To demonstrate that the protein migrating at ,~,35.5 kD was 
responsible for the antiangiogenic activity, we conducted the 
gel elution experiments described in Materials and Methods. 
Material eluted from each of the zones as described above 
was tested for its ability to inhibit FGF-stimulated capillary 
EC proliferation as  well as for its ability to inhibit mam- 
malian collagenase. Only protein corresponding to the band 
at Mr 35,500 inhibited capillary EC proliferation, doing so 
in a dose-responsive manner (Fig. 5 c). This material also 
inhibited collagenase in the radiometric enzyme assay (IC5o 
=  51.15 ng/ml). 
To determine whether the inhibition of capillary EC pro- 
liferation was due to cytotoxicity, reversibility studies were 
conducted as described previously (3, 8, 36). These studies 
showed that not only did the endothelial cells grow normally 
after removal of the inhibitor, but these cells were also capa- 
ble of responding to mitogen to the same degree as did con- 
trol cells never exposed to ChDI. 
To examine the specificity of the inhibitor's antiprolifera- 
tive effect, we tested other substances  for their ability to 
inhibit capillary EC proliferation. Other enzyme inhibitors 
such as  trypsin ovoinhibitor,  ~2  macroglobulin (a  colla- 
genase inhibitor), and chondroitin sulfate (a glycosamino- 
glycan found in cartilage) did not have a  significant effect 
(<20%  inhibition  or  stimulation,  at  all  doses  tested)  on 
growth  factor-stimulated capillary  EC  proliferation even 
when tested at concentrations of 50 #g/ml.  These factors 
also do not inhibit angiogenesis in vivo (36). 
Given that capillary EC migration in response to a stimu- 
lus is another key component of the angiogenic process (1), 
we tested the chondrocyte CM and ChDI derived from G-75 
columns eluted in the absence of 4  M  guanidine-HC1  for 
their ability to inhibit bFGF-stimulated EC migration using 
a modification (10) of  the Boyden assay. Chondrocyte CM in- 
hibited growth factor-stimulated capillary EC migration at 
an IC5o of 28 #g/mi and ChDI inhibited at an IC50 of 255 
ng/ml (Fig. 6). 
The Journal  of Cell  Biology,  Volume  119, 1992  478 Figure 4. Inhibition of angiogenesis by ChDI. On day 3 of  development, fertilized chick embryos were removed from their shells and placed 
in plastic petri dishes.  They were maintained  in humidified 5%  CO: at 37~  On day 6 of development, 4-~tg samples of ChDI were 
mixed in methylcellulose disks and applied to the surfaces of the growing CAMs. After 48 h exposure of the CAMs to ChDI, avascular 
zones, free of capillaries and small vessels were observed using a binocular dissecting microscope at ￿  magnification. The CAMs 
were injected intravascularly with India ink/Liposyn  as described  previously (50).  The centers of the avascular zones are free of India 
ink-filled capillaries and contain the methylcellulose disks (a). A normal CAM containing an empty methylcellulose disk is shown in b. 
Histological sections of day 8 CAMs reveal normal capillary development in untreated controls (d) in comparison to ChDI-treated CAMs 
(c).  22 embryos were used.  All tests were conducted double-blind. 
Discussion 
Neovascularization is a  complex process characterized by 
penetration of basement membrane by capillary EC, migra- 
tion of cells through matrix towards a stimulus, and subse- 
quent  proliferation  0,  11). Although  the  role  of various 
growth factors in the process of vascular proliferation has 
been well characterized (12), relatively little is known about 
the identity or role of naturally occurring inhibitors of neo- 
vascularization (31).  Due to previously reported difficulties 
in obtaining or purifying biologically active inhibitory mate- 
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rial from human and animal tissue extracts, alternate sources 
of antiangiogenic  factors have recently begun to be explored 
(3I).  The studies reported here demonstrate that  scapular 
chondroeytes established and maintained in serum-free cul- 
ture produce a potent inhibitor of angiogenesis  in vivo. The 
FigureS.  Effect of chondrocyte CM and ChDI on aFGF-stimulated 
capillary  EC proliferation. Capillary ECs (10  ~ cells/0.5 ml DME/5) 
were plated onto gelatin-coated 24-well tissue culture dishes and 
allowed to attach overnight. On day 2, unattached cells were re- 
moved and attached cells were refed with DME/5.  Inhibitor and 
aFGF (12 ng/ml) were added. Wells containing PBS alone and PBS 
+  aFGF were included as controls. On day 5, medium was aspi- 
rated, cells were washed with 0.5 ml of  PBS, removed by trypsiniza- 
tion, and counted, a and b demonstrate the antiproliferative effect 
of  increasing  concentrations of  chrondrocyte CM and ChDI, respec- 
tively, on capillary EC proliferation. Control wells containing PBS 
alone contained 75,630  :k  129.45 cells (a)  10,807 5:911.67 cells 
(b) and  18,907  5:129.45 cells (c). a  and b are representative of 
three separate experiments (b is representative of three separate 
Sephadex G-75 column runs); c is representative of two separate 
experiments and demonstrates the antiproliferative activity of in- 
creasing amounts of chrondrocyte-derived angiogenesis inhibitor 
corresponding to an Mr of 35,500 obtained from the gd elution 
experiments. Percent inhibition was determined by comparing the 
cell number of wells exposed to stimulus with those exposed to 
stimulus and inhibitor. Each data point of each experiment repre- 
sents the mean of triplicate wells; SEM was <3%  of the mean. 
potency of this inhibitor can be appreciated when compared 
to that of other irthibitors  of neovascularization  previously 
reported. Other angiogenesis inhibitors  (e.g., vitreous, prot- 
amine, platelet factor 4, AGM-1470, and others (14, 23, 30, 
50) required doses of 10-100 #g of material to obtain ',,50% 
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I  lary EC migration by ChDI. 
Migration of  capillary EC was 
measured using  a  modifica- 
~.  tion of the Boyden chamber 
.~  assay as described by us pre- 
~  viously  (36). FGF  (Takeda 
F 
~-  Co., Osaka, Japan) diluted in 
DME/1 (29/~1) was added to 
,5c  the lower wells at a concentra- 
.~  tion of 10 ng/ml. The upper 
wells received 50/~1 of a cell 
c-~o  Q2~  ~  suspension  containing  5  x 
lC~Dll  u~m/ 
IO  s capillary  EC/ml and in- 
creasing  concentrations  of  ChDI. Control  wells  received  DME~, 
either  with or without bFGE The migration  chambers were in- 
cubated at 37~  in 10% CO: for  4 h. Each point  represents  the 
mean •  SEM of four  wells.  In control  wells  without  bFGF, the 
number of  migrated capillary  ECs was 186 • 4 SEM. 
avascular zones,  whereas just 4  t~g of ChDI caused 87 % 
avascular zones. 
It is interesting to note that this chondrocyte-derived an- 
tiangiogenic protein (ChDI)  is also an inhibitor of mam- 
malian collagenase. Although it has been known that chon- 
drocytes synthesize proteases and some of their modulators 
(activators and inhibitors), it has been assumed that these 
macromolecules are produced solely for the purpose of syn- 
thesizing and remodelling the cartilage extracellular matrix 
(52).  This work demonstrates an additional function for a 
negative modulator of collagenase activity. 
This report represents the first demonstration that a chon- 
drocyte-derived collagenase inhibitor can inhibit angiogene- 
sis in vivo. In 1984,  Bunning and co-workers reported that 
a collagenase inhibitor produced by bovine nasal cartilage 
and articular chondrocytes did not inhibit angiogenesis on 
the chick CAM (5). Takigawa, Shirai, and co-workers subse- 
quently reported that undefined extracts of articular cartilage 
and articular chondrocyte CM contain an inhibitor of angio- 
genesis (49); whether these extracts contain collagenase in- 
hibitory activity is still not known. 
This study also confirms earlier reports which noted the 
production of collagenase inhibitors by articular chondro- 
cytes. A number of groups have shown that metalloproteinase 
inhibitors are produced by chondrocytes in culture, yet until 
now, the physiological significance of such an inhibitor re- 
mained unknown. These inhibitors include a partially pu- 
rified collagenase inhibitor having an Mr of 32,000 isolated 
from the conditioned media of bovine articular chondrocytes 
as reported by Bunning and co-workers (5) and Murphy et 
al. (37), a partially purified collagenase inhibitor having an 
Mr of 35,000 from the same source as described by Morales 
and co-workers (32) and a higher molecular weight collagen- 
ase inhibitor made by rabbit articular chondrocytes in cul- 
ture (Mr 66,000) described by Morris (33). 
Whether ChDI is identical to the tissue-derived inhibitor 
of angiogenesis (CDI) or to other chondrocyte-derived col- 
lagenase inhibitors remains to be seen since lack of sequence 
information of these chondrocyte factors precludes direct 
comparison. We are currently conducting studies to obtain 
sequence information for ChDI. We note here that in terms 
of its capillary EC antiproliferative activity, the specific ac- 
tivity of ChDI is virtually the same as that reported for CDI, 
the cartilage~erived angiogenesis inhibitor CiC5o of 62.5 
nM) (36). ChDI is a slightly more potent flC~0 of 7.18 riM) 
inhibitor of capillary EC migration than is CDI (IC5o of 16 
nM). In terms of its antiangiogenic activity in vivo ChDI is 
at least as potent an inhibitor of neovascularization as CDI 
(36). ChDI differs from CDI in its apparent Mr (35,500 and 
27,650 respectively) as determined by both gel filtration and 
SDS-PAGE  analysis. 
Differences in molecular weight between ChDI and other 
chondrocyte-derived collagenase inhibitors may be ascribed 
to differences in the types of cartilage (articular or scapular) 
used as a source of chondrocytes, species variations (bovine 
or rabbit), the conditions under which these cultures were 
established and maintained (with or without serum), differ- 
ences in purification methods, and the potential existence of 
different members of a family of related metalloproteinase 
inhibitors (35, 48). 
Difficulties in obtaining and purifying biologically active 
inhibitory material from human and animal tissue extracts 
have greatly limited the identification and availability of an- 
giogenesis inhibitors. The fact that these primary chondro- 
cyte cultures were established and maintained in serum-free 
culture greatly facilitated purification of ChDI by eliminating 
the need to remove any contaminating serum-derived proteins 
as well as by eliminating any effect that these serum-derived 
factors might have on normal chondrocyte secretion (33). 
These studies suggest that ChDI may be at least one of the 
molecules  responsible  for  the  maintenance of cartilages 
avascularity. A number of serious connective tissue patholo- 
gies including rheumatoid arthritis can be characterized by 
persistent and deregulated angiogenesis (12,  17, 44) as well 
as by uncontrolled extracellular matrix degradation (6). The 
further study of ChDI, as a chondrocyte-derived antiangio- 
genie factor, may lead to potential therapeutic agents for the 
treatment of  the large number of serious diseases, connective 
tissue and otherwise, which might be controlled via the use 
of an antiangiogenic strategy. 
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